Table 2:
Association between gut microbiome diversity and clinical outcomes in participants from both arms of the study
| Clinical outcome | Number of events |
Microbiome diversity at engraftment |
Microbiome diversity at baseline |
||
|---|---|---|---|---|---|
| P value | Hazard ratio (95% interval) |
P value | Hazard ratio (95% interval) |
||
| Non-relapse mortality |
22 [at 12 months] |
0.314b | 0.804 (0.526, 1.229) |
0.057b | 0.631 (0.393, 1.014) |
| Relapse/Progression |
62 [at 12 months] |
0.442b | 1.092 (0.873, 1.365) |
0.047 a | 0.389 (0.178, 0.849) |
| Acute GVHD [Grade II - IV] |
107 [after 100 days] |
0.060b | 0.836 (0.693, 1.008) |
0.121b | 0.803 (0.608, 1.060) |
| Acute GVHD [Grade III - IV] |
18 [after 100 days] |
0.075b | 0.710 (0.487, 1.035) |
0.032 b | 0.610 (0.388, 0.958) |
| Chronic GVHD |
60 [at 12 months] |
0.304b | 1.130 (0.896, 1.425) |
0.119a | 2.121 (1.018, 4.418) |
| Moderate/severe chronic GVHD |
23 [at 12 months] |
0.333b | 1.231 (0.808, 1.875) |
0.027 a | 3.821 (1.233, 11.837) |
| Overall Survival |
55 [at 12 months] |
0.178b | 0.846 (0.664, 1.079) |
0.007 b | 0.631 (0.452, 0.881) |
| GVHD-free, relapse-free survival |
124 [at 12 months] |
0.740b | 0.972 (0.824, 1.148) |
0.047 b | 0.786 (0.620, 0.996) |
a:
Diversity considered as tertiles
b:
Diversity considered as linear predictor; model chosen by AIC